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Introduction: Adjuvants and immunotherapies designed to activate adaptive immunity to
eliminate infectious disease and tumors have become an area of interest aimed at providing
a safe and effective strategy to prevent or eliminate disease. Existing approaches would
benefit from the development of immunization regimens capable of inducing efficacious cell-
mediated immunity directed toward CD8+ T cell-specific antigens. This goal is critically
dependent upon appropriate activation of antigen-presenting cells (APCs) most notably
dendritic cells (DCs). In this regard, polyanhydride particles have been shown to be effec-
tively internalized by APCs and induce activation.
Methods: Here, a prophylactic vaccine regimen designed as a single-dose polyanhydride
nanovaccine encapsulating antigen is evaluated for the induction of CD8+ T cell memory in
a model system where antigen-specific protection is restricted to CD8+ T cells. Bone
marrow-derived dendritic cells (BMDCs) are used as an in vitro model system to evaluate
the magnitude and phenotype of APC activation. Primary DCs, particularly those with
described ability to activate CD8+ T cells, are also evaluated for their in vitro responses to
polyanhydride nanoparticles.
Results: Herein, polyanhydride nanoparticles are shown to induce potent in vitro upregulation
of costimulatorymolecules on the cell surface of BMDCs. In contrast to the classically used TLR
agonists, nanoparticles did not induce large amounts of pro-inflammatory cytokines, did not
induce characteristic metabolic response of DCs, nor produce innate antimicrobial effector
molecules, such as nitric oxide (NO). The polyanhydride nanovaccine results in protective
CD8+ T cell responses as measured by inhibition of tumor progression and survival.
Discussion: Together, these results suggest that the use of a polyanhydride-based nanovac-
cine can be an effective approach to inducing antigen-specific CD8+ T cell memory by
providing antigen delivery and DC activation while avoiding overt inflammatory responses
typically associated with traditional adjuvants.
Keywords: nanovaccine, metabolism, nitric oxide, T cell memory, inflammation
Introduction
Cytotoxic CD8+ T cells are critical mediators of immunological protection against
tumors and intracellular pathogens.1 Although naturally occurring infections are often
effective at inducing long-lived CD8+ T cell memory, commonly used adjuvants such
as alum, oil-in-water emulsions, or innate immune stimulating Toll-like receptor (TLR)
ligands have not proven as successful for the induction of cell-mediated immunity
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(CMI).2 Many efficacious immunization strategies that
induce rapid and robust/durable memory CD8+ T cell
responses have either employed a multiple-dose regimen
(ie, prime-boost) or treated animals with adoptively trans-
ferred DCs pulsed in vitro with antigen.3–5 Single-dose DC
vaccines that rapidly induce a large number of memory CD8+
T cells possess the relatively unique property of providing
both antigen presentation and co-stimulation without the
induction of overt inflammatory responses that result when
using more standard antigen-adjuvant combinations or
infections.4 Many adjuvants are incorporated into vaccine
formulations to induce inflammation and innate immune
activation with a focus on the induction of long-lived anti-
body titers as opposed to CMI.2 While beneficial to antibody
tiers, adjuvant-associated proinflammatory cytokines and
associated inflammation have been demonstrated to divert
an intrinsic CD8+ T cell pathway towards induction of effec-
tor memory T cells. It has also been shown that overt inflam-
matory responses impair effector CD8+ T cell trafficking and
function.4,6,7 These blunted T cell responses result in less
effective generation of memory or effector T cells.4,6,7
Another common class of adjuvants, TLR agonists, not
only induce the production of proinflammatory cytokines
and overt inflammation but also induce innate immune effec-
tor molecules such as nitric oxide (NO).8–10 Nitric oxide in
particular has been described to cause deleterious effects on
DC activation via altered metabolism, decreased survival,
and impaired co-stimulatory molecule upregulation.11–13
Although effective at generating rapid and elevated numbers
of memory CD8+ T cells, the use of DC vaccines also comes
with increased costs and the challenges associated with the
personalized nature of generating ex vivo DC populations to
be used therapeutically.14 Consequently, identification and
development of novel, less inflammatory vaccine adjuvants
and antigen delivery systems would benefit the induction of
favorable outcomes using a more manageable immunization
regimen.
To improve vaccines’ ability to induce optimal cytotoxic
CD8+ T cell memory, design of vaccine delivery systems
that mimic the beneficial effects of DC vaccination (ie,
MHC I presentation of antigen) could be used.
Polyanhydride particle-based vaccines in particular repre-
sent a unique alternative to existing vaccines that employ
more traditional adjuvants. Nanoparticles (NPs) consisting
of combinations of sebacic acid (SA), 1,6-bis(p-carboxyphe-
noxy)hexane (CPH), and 1.8-bis(p-carboxyphenoxy)-
3,6-dioxaoctante (CPTEG) are readily phagocytosed by
DCs and activate them as measured by cytokine and
costimulatory molecule upregulation.15 Following adminis-
tration in vivo, these nanovaccines are also known to persist
in the local tissues, thus, facilitating the prolonged release of
their encapsulated payload.16,17 When delivered subcuta-
neously, polyanhydride NPs induce a mild inflammatory
response with no evidence of adverse histopathological
reactions.16,18 Previous studies have also illustrated the abil-
ity of polyanhydride NPs to prophylactically enhance CD8+
T cell memory responses and elicit protection in a tumor
challenge model.19 However, the addition of a TLR ligand
such as CpG oligodeoxynucleotides (ODN) to the polyanhy-
dride platform decreased relative efficacy indicating that the
induction of inflammation adversely affected the generation
of effector CD8+ T cell responses.19,20 Considering the
unique innate immune stimulatory properties of polyanhy-
dride NPs, the ability of this platform to activate DCs and
induce an effective memory CD8+ T cells was tested and
compared to the inflammatory TLR agonist CpG ODN. This
was evaluated via an ovalbumin (Ova)-expressing tumor
model where Ova is expressed cytosolically and antigen-
specific protection is restricted to MHCI:CD8+ T cell-
mediated immune responses.21–24
Materials and Methods
Materials Synthesis
Chemicals used for the polymer and nanoparticle synth-
esis, 4-p-hydroxybenzoic acid, tri-ethylene-glycol, and
1,6-dibromohexane were obtained from Sigma Aldrich
(St. Louis, MO); dimethylformamide, acetic acid, acetoni-
trile, acetic anhydride, toluene, methylene chloride, pen-
tane were purchased from Fisher Scientific (Fairlawn, NJ)
and 4-p-flourobenzonitrile was purchased from Apollo
Scientific (Cheshire, UK).
Polyanhydride Synthesis
Monomers of CPTEG and CPH were synthesized and used
in a 20:80 molar ratio to synthesize a 20:80 CPTEG:CPH
copolymer via melt polycondensation reaction as pre-
viously described.25 The purity and molecular weight of
the copolymer was characterized using 1H nuclear mag-
netic resonance spectroscopy in deuterated chloroform.
The molecular weight of the copolymer was about 5.3
kDa, consistent with previous work.26
Nanoparticle Synthesis
20:80 CPTEG:CPH nanoparticles encapsulating 5 wt.%
Ova were synthesized using flash nanoprecipitation as
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previously described.27 Briefly, a solution of 20:80
CPTEG:CPH and ovalbumin in methylene chloride at
a concentration of 20 mg/mL was poured into pentane at
a solvent to anti-solvent ratio of 1:250. The nanoparticles
were then collected using vacuum filtration. The particle
morphology and size were examined using scanning elec-
tron microscopy. The average particle size of nanoparticles
used for these studies was about 200 nm.
Animals
Female BALB/c mice, aged six to eight weeks, were
obtained from Charles River Laboratories (Wilmington,
MA) for in vitro studies. Female C57BL/6 mice, aged six
to eight weeks, were obtained from Charles River and
Envigo (Somerset, NJ). Studies involving the use of mice
were conducted in accordance with Iowa State University
guidelines for the care and use of animals and upon approval
of the Institutional Animal Care and Use Committee.
Cell Culture
The E.G7-OVA (ATCC, Manassas, VA) cell line was cul-
tured and maintained in RPMI 1640 (Cat #10-040-CM,
Corning) medium containing 2 mM L-glutamine 1.5 g/L
sodium bicarbonate, 4.5 g/L glucose, 10 mMHEPES, 1 mM
sodium pyruvate, 0.05 mM 2-mercaptoethanol, 0.4 mg/mL
G418 (Cat #30-234-CI, Cellgro), 100 U/mL penicillin, 100
µg/mL streptomycin, and 10% fetal bovine serum. The EL4
(ATCC) cell line was culture and maintained in DMEM
(Cat #15-013-CV, Corning) supplemented with 2 mM
L-glutamine, 100 U/mL penicillin, 100 µg/mL streptomy-
cin, and 10% horse serum.
Bone Marrow DC Generation
Naïve female BALB/c mice were used to generate BMDC
cultures. Bone marrow was collected from femurs and
tibias. Cells were washed and plated in RPMI 1640 med-
ium supplemented with 100 U/mL penicillin and 100 μg/
mL streptomycin, 2 mM glutamine, and 10% FBS in
100 mm petri plates, at a density of 4 x 106 bone marrow
cells per plate with 10 mL of medium supplemented with
GM-CSF (Peprotech, Rocky Hill, NJ) at 10 ng/mL.
On day three of culture, 10 mL of GM-CSF containing
medium was added. On days six and eight of culture,
10 mL of culture medium was exchanged for fresh GM-
CSF containing medium. DCs were harvested on day 10 of
culture by gently rinsing and collecting non-adherent cells.
Splenic DC Isolation
Naïve female BALB/c mice were euthanized to collect
spleens. Spleens from eight to ten mice were harvested,
pooled, and used to generate a population of single cells.
Using these splenocytes, highly enriched populations of
DCs were recovered using a pan-DC isolation kit (13–100-
875) (Miltenyi Biotec, Auburn, CA) on an autoMACS Pro
separator (Miltenyi Biotec) according to manufacturer’s
protocol.
BMDC and sDC Stimulation
DCs were plated at 5 x 105 cells/well in a 96-well round
bottom tissue culture plate in 200 μL of RPMI 1640
medium supplemented with 100 U/mL penicillin and 100
μg/mL streptomycin, 2 mM glutamine, and 10% FBS. The
in vitro treatments consisted of 100 μg/well of 20:80
CPTEG:CPH NPs encapsulating 5 μg of Ova, 5 μg/mL
of CpG ODN 1668 (Cat #16E17-MM InvivoGen) with 5
μg Ova, or medium alone (ie, control wells). After the
addition of the stimulants, the BMDCs were incubated for
48 h after which supernatants and cells were harvested for
cytokine analysis and cell surface marker expression by
flow cytometry, respectively.
Nitric Oxide Quantification
Supernatants from stimulated DCs were analyzed for NO
indirectly via nitrite concentration by Griess assay.
A standard curve was created using two-fold dilutions of
sodium nitrite ranging from 100 μM to 0 μM. One hundred
microliters of supernatant was incubated with 100 μL of
Griess reagents (Cat. No. 03553, Sigma-Aldrich) in a 96-
well microtiter plate. Samples were incubated for 15 min
at room temperature and read at 540 nm on a SpectraMAX
190 (Molecular Devices, Sunnyvale, CA).
Extracellular Flux Analysis
BMDCs from BALB/c mice were stimulated in RPMI
1640 medium supplemented with 100 U/mL penicillin
and 100 μg/mL streptomycin, 2 mM glutamine, and
10% FBS for 18 h with 100 μg of 20:80 CPTEG:CPH
encapsulating 5 μg of Ova, 5 μg/mL of CpG ODN with
5 μg Ova, or no stimulation control in 5 mL polypro-
pylene tubes. Treated BMDCs were washed with
Seahorse assay media consisting of Agilent Seahorse
XF Base medium (Cat #102,353, Agilent, Santa Clara,
CA) supplemented with 1 mM sodium pyruvate, 2 mM
L-glutamine, and 10 mM glucose with a pH adjusted to
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7.4, were seeded into 24-well seahorse plates coated
with Cell-Tak (Corning, Corning NY) at a density of
2.5 x 105 cells per well. Metabolic phenotyping was
conducted on a Seahorse XFe24 (Agilent).
Mitochondrial function was analyzed via mitochondrial
stress test according to manufacturer specifications.28
Final concentrations of 1 μM oligomycin, 2 μM FCCP,
and 0.5 μM rotenone and antimycin were used (Agilent)
and prepared in Seahorse assay medium.
Vaccination
Two antigen doses were evaluated in the in vivo studies.
In the high antigen dose (2.0 mg Ova) studies, female
C57BL/6 mice were vaccinated with formulations con-
sisting of 250 μg Ova encapsulated in 5 mg of 20:80
CPTEG:CPH (5% loaded) plus 1.75 mg Ova soluble
(NP), 2 mg soluble Ova (sOva), or unvaccinated control.
In the prime-boost experiment, the mice were vaccinated
with formulations consisting of 1.75 mg sOva along
with 5 mg of 20:80 CPTEG:CPH polyanhydride nano-
particles encapsulating 250 µg Ova with and without
a boost (NPx1, NPx2), 2 mg soluble Ova with 5 mg
of blank 20:80 CPTEG:CPH polyanhydride nanoparti-
cles (Blank NP x2), or PBS control. Mice that received
a booster (indicated by x2) were given the same formu-
lations at half the original dose of antigen and particle
mass. In the low antigen dose (100 µg Ova) studies,
mice were vaccinated with formulations consisting of 75
µg soluble Ova plus 500 µg of 20:80 CPTEG:CPH
polyanhydride nanoparticles encapsulating 25 µg Ova
(NP), 100 µg soluble Ova (sOva), or PBS control. In
the multi-adjuvant experiment, mice received formula-
tions consisting of 75 µg soluble Ova plus 500 µg of
20:80 CPTEG:CPH polyanhydride nanoparticles encap-
sulating 25 µg Ova (NP), 100 µg soluble Ova adju-
vanted with 20 µg CpG ODN 1668 (CpG),
a combination of 75 µg soluble Ova plus 500 µg of
20:80 CPTEG:CPH polyanhydride nanoparticles encap-
sulating 25 µg Ova adjuvanted with 20 µg CpG ODN
(NP+CpG), or PBS control. All formulations were deliv-
ered subcutaneously at the nape of the neck.
Tumor Challenge
C57BL/6 mice were challenged subcutaneously on the
flank with 2–5 x 106 E.G7 Ova-expressing lymphoma
cells or 2.5 x 106 EL4 lymphoma cells that had been
washed and suspended in PBS prior to implantation.
Tumor growth was monitored three times a week and
volumes were calculated by using the equation to
determine the volume of an ellipsoid (see below).
Mice were removed from study when tumor volume
surpassed 1000 mm3. As mice did not succumb to the
tumor and were removed based on the criteria of tumor
volume, time on study is presented for survival
analysis.
Tumor volume (V) = (4/3)π r1r2r3.
Cytokine and Chemokine Analysis
Cytokine quantification was performed using supernatants
from the previously described DC stimulations.
A Millipore Milliplex cytokine/chemokine panel
(MCYTOMAG-70K-32, Burlington, MA) was used to
detect cytokines and analyzed on a Bio-Plex 200 System
(Bio-Rad, Hercules, CA) according to manufacturer’s
specifications.
Flow Cytometry
Splenic DCs and BMDCs were analyzed for costimulatory
marker expression using flow cytometry. 5 x 105 DCs were
aspirated from a 96-well plate and transferred to FACS
tubes. Prior to labeling with specific monoclonal antibo-
dies, Fc receptors on DCs were blocked to prevent non-
specific antibody binding by incubating the cells with 100
μg/mL of rat IgG (Sigma Aldrich) and 10 μg/mL of anti-
CD16/32 (eBioscience, San Diego, CA). Subsequently,
DCs were stained with fluorescently conjugated antibodies
specific for CD80 (Biolegend, San Diego, CA, PerCP-
Cy5.5, clone 16–10A1), CD86 (eBioscience, FITC, clone
GL1), CD40 (eBioscience, APC, clone 1C10), CD11c
(Biolegend, APC-Cy7, clone N418), MHCII
(eBioscience, AF700, clone M5/114.15.2), and CD8α
(Biolegend, BV421, clone 53–67) diluted in PBS contain-
ing 0.1% bovine serum albumin (BSA) and 0.1% sodium
azide. Cells were fixed using BD stabilizing fixative (BD
Bioscience, Franklin Lakes, NJ). Mitochondrial superox-
ide production was evaluated using live cells stained with
MitoSOX Red (Cat # M36008, Invitrogen, Carlsbad, CA)
according to manufacturer’s specifications. All data were
collected on a FACSCanto II (BD Bioscience, Franklin
Lakes, NJ). Data were analyzed using FlowJo (FlowJo
LLC, Ashland, OR).
Antibody Responses
Where applicable, immunized mice were bled via saphe-
nous vein 5 weeks post-immunization. Anti-Ova serum
IgG titers were measured via indirect ELISA. Costar
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3590 96-well EIA/RIA high binding plates (Corning) were
coated with 100 µL of Ova (5 µg/mL PBS) or PA (0.5 µg/
mL PBS) and incubated overnight at 4°C. Plates were
blocked using 2.5% (w/v) powdered skim milk PBS con-
taining 0.05% Tween-20 (PBS-T), that has been heat inac-
tivated at 56°C for hours to inactivate any phosphatase
activity, for two hours at room temperature. After three
washes using PBS-T, serum samples were titrated across
the plate using two-fold serial dilutions, starting at 1:100,
in PBS-T and 1% (v/v) normal goat serum. Samples were
incubated overnight at 4° C. After three washes in PBS-T,
an alkaline phosphatase-conjugated goat anti-mouse IgG
(H+L) secondary detection antibody (Cat# 115–005-003,
Jackson ImmunoResearch, West Grove, PA) was diluted
1:1000 in PBS-T and added to the wells and allowed to
incubate at room temperature for two hours. Plates were
washed three times with PBS-T and alkaline phosphatase
substrate was added at 1 mg/mL in buffer containing 50
mM sodium carbonate, 2 mM magnesium chloride, and
sodium bicarbonate was titrated into the solution in order
to achieve a pH of 9.3. Plates were allowed to develop for
30 min and analyzed using the SpectraMAX 190 at
a wavelength of 405 nm.
Statistical Analysis
Data generated during flow cytometry assays, metabolic
assays, and Griess assays were analyzed via one-way
ANOVAwith a Tukey, Dunnett, or Sidak post-test for multi-
ple comparisons. Survival data were analyzed using a Log
rank (Mantel-Cox) test with a Bonferroni correction for
multiple comparisons. All analyses were performed using
GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA).
Results
High Antigen Dose Polyanhydride
Nanoparticle vaccination Reduced Tumor
Burden and Increased Time on Study
Previous studies from our laboratories have shown that immu-
nization with a high dose (ie, 2 mg) of Ova in a polyanhydride
particle-based vaccine regimen induced OTI CD8+ T cell
memory and the ability of these CD8+ T cells to expand upon
reencounter with antigen.27 Herein, the ability of polyanhy-
dride nanoparticles to induce efficacious endogenous antigen-
specific CD8+ T cell memory and subsequent effector expan-
sion upon challenge was evaluated using a tumor challenge
model, where antigen-specific protection is restricted to CD8+
T cell:MHCI recognition. C57BL/6 mice were vaccinated
prophylacticallywith high antigen dose (2.0mgOva) formula-
tions consisting of polyanhydride nanoparticles (NP) (charac-
terization data of theNPs are shown in Supplemental Figure 1),
sOva alone, or a PBS control. Six weeks later, mice were
challenged subcutaneously by implanting Ova-expressing E.
G7 tumor cells or EL4 tumor cells (ie, do not expressOva), and
tumor progression was tracked. Vaccination with the NP for-
mulation reduced tumor progression in comparison to naïve
mice and mice immunized with the sOva alone (Figure 1A).
NP vaccination also significantly improved time on study (ie,
% of mice with tumors <1000 mm3) compared to control
animals (Figure 1C). No significant improvements in survival
were observed for mice receiving sOva alone compared to
controls.
To determine whether antigen-specific immune activa-
tion was responsible for the observed anti-tumor responses,
another set of mice was challenged with the EL4 parent
tumor that does not express Ova (Figure 1B and D).
Neither the NP formulation nor sOva significantly improved
time on study after subsequent tumor challenge (Figure 1B
and D). Together, these data demonstrate that the NP formu-
lation is able to induce efficacious antigen-specific, memory
CD8+ Tcells capable of responding to re-exposure to antigen
(ie, tumor implantation).
Encapsulation of Antigen in Polyanhydride
NPs is Critical for Inducing Optimal
CD8+ T Cell Memory
Even though the high antigen dose (2.0 mg Ova) vaccine
formulation contained a large amount of unencapsulated solu-
ble antigen (1.75 mg), we hypothesized that the portion of
antigen encapsulated within the polyanhydride NPs would be
more important to the induction of CD8+ T cell memory than
the soluble bolus. This hypothesis was tested by vaccinating
C57BL/6 mice with a single-dose NP formulation, a prime-
boost of the same NP formulation, a prime-boost of blank NPs
with no encapsulated antigen (ie, soluble Ova only), or inject-
ing PBS alone (ie, control). Six weeks after their last immu-
nization, all mice were challenged subcutaneously with the
Ova-expressing E.G7 tumor, and the tumor progression and
time on study for each treatment compared (Figure 2A and B).
The only treatments that significantly inhibited tumor progres-
sion compared to PBS injections were the single-dose NP (NP
x1) and the prime-boost NP (NP x2) regimens. Mice immu-
nized twice with blank NPs (x2) plus sOva tended to have an
Dovepress Darling et al
International Journal of Nanomedicine 2020:15 submit your manuscript | www.dovepress.com
DovePress
6583
improved median survival time compared to naïve control
mice; however, this difference was not significant.
Polyanhydride NPs Upregulated
Co-Stimulatory Molecule Expression on
DCs but Resulted in Low Levels of
Inflammatory Cytokine and Chemokine
Production
Previous work on polyanhydride particle formulations illu-
strated that bone marrow-derived dendritic cells (BMDCs)
readily take up and respond to these particles by upregu-
lating co-stimulatory molecules and cytokine secretion
similar to other pathogen-mimicking moieties.15,17,29 The
low inflammatory response induced by polyanhydride NP
vaccines is similar to that induced by DC-based vaccines
that support the induction of CD8+ T cell memory.18
Herein, the ability of the 20:80 CPTEG:CPH polyanhy-
dride NP formulation to activate BMDC was compared to
the effects of CpG ODN. After 48 h of in vitro stimulation
with NPs or CpG ODN, BMDCs significantly (P < 0.05)
upregulated the co-stimulatory molecules CD86 and CD40
as compared to non-stimulated BMDCs (Figure 3A).
Supernatants from stimulated BMDCs were also evaluated
for induction of inflammatory cytokine and chemokine
production. Other than MIP2, CXCL1 (KC), and IL-6,
the NP formulation induced secretion of markedly less
inflammatory cytokines when compared to that induced
by CpG ODN (Supplemental Figure 2).
Dendritic cell populations isolated from the spleens of
naïve mice were also evaluated for their response to stimula-
tion. Splenic DCs (sDC) were stimulated with either the NP
Figure 1 Polyanhydride nanoparticles enhance CD8+ T cell memory generation with high dose antigen. C57BL/6 female mice were immunized subcutaneously with
formulations consisting of 1.75 mg soluble Ova plus 5 mg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 250 μg Ova (NP); 2 mg soluble Ova (sOva); or
PBS (control). Mice were challenged subcutaneously in the flank with (A) EG7OVA Ova-expressing tumor cells (n=12 all groups) or (B) non-Ova expressing EL4 tumor cells
(n=4) 40 days post-immunization and tumor volume of individual mice was tracked. Survival of mice receiving (C) EG7OVA tumor or (D) EL4 tumor was evaluated 30 days
post-challenge. Significance from PBS control was determined using a Log rank (Mantel-Cox) test with a Bonferroni correction for multiple (2) comparisons. Significance
from naïve control is indicated in the treatment group legend as follows *p ≤ 0.025. Median survival of each group is also reported parenthetically.
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formulation or CpG ODN for 48 h. The CD11c+ population
of the sDC was evaluated for upregulation of the costimula-
tory molecules CD86 and CD40 (a gating diagram is shown
in Supplemental Figure 3). The NP formulation upregulated
CD86 and CD40 expression while CpG ODN only upregu-
lated CD40 as compared to non-stimulated sDC (Figure 3B).
The CD8α+ subpopulation of sDC has been previously
reported to cross-prime CD8+ T cells.4,30–32 To determine
Figure 2 Encapsulated antigen is crucial to induce antigen-specific CD8+ T cell memory. C57BL/6 female mice were immunized subcutaneously at the base of the neck with
formulations consisting of 1.75 mg soluble Ova with 5 mg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 250 μg Ova with (NP x2) and without a boost
(NP x1) (n=16); 2 mg soluble Ova with 5 mg of blank 20:80 CPTEG:CPH polyanhydride nanoparticles (Blank NP x2) (n=8); or PBS control (n=16). Mice that received
a booster (NP x2) were given the same formulations at half the original dose subcutaneously at the base of the neck 28 days after the primary immunization. Mice were
challenged subcutaneously in the flank with E.G7 Ova-expressing tumor cells 42 days after the primary or boost immunization, respectively. (A) Tumor volume of individual
mice was tracked. (B) Survival was evaluated 31 days post-challenge. Statistical significance was determined using a Log rank (Mantel-Cox) test with a Bonferroni correction
for multiple (6) comparisons. Significance from naïve control group is indicated in the treatment group legend as *p ≤ 0.0083. Median survival of each group is also reported
parenthetically. (C) Diagram of vaccination schedule. 1 ° = primary vaccination, 2 ° = primary vaccination, following which all mice received an injection of E.G7 tumor cells
as described in Materials and Methods.
Dovepress Darling et al
International Journal of Nanomedicine 2020:15 submit your manuscript | www.dovepress.com
DovePress
6585
whether NP stimulation activated CD8α+ sDC, we measured
co-stimulatory marker expression on CD8α+ sDC. CpG
ODN induced only a moderate upregulation of co-
stimulatory molecules on CD8α+ sDC; however, NP stimula-
tion induced a marked increase in the expression of CD86,
CD80, and CD40 (Figure 3C). These findings suggest that
NPs are capable of activating a critically important DC sub-
type involved in the presentation of antigen to and activation
of CD8+ T cells. Supernatants from the total population of
stimulated sDC were also evaluated for cytokine production
via a multiplex assay. As observed for the BMDCs, a lower
magnitude of inflammatory cytokine and chemokine
responses were observed for NP stimulated sDC compared
to those induced by CpG ODN (Supplemental Figure 4.)
Polyanhydride Nanoparticles Activate
BMDCs Without Inducing Innate Effector
Molecules or Altering Cellular Metabolism
Upon natural infection or after stimulation with TLR ligands
such as CpG ODN, activated APCs produce innate effector
molecules such as NO or reactive oxygen species (ROS).
Although these molecules provide critical microbicidal activity
during acute infections,33,34 NO and ROS can also have inhi-
bitory effects on innate11,13,35 and adaptive13,36–39 immune
responses. After 48 h of in vitro stimulation, NO production
by BMDCwas measured indirectly by assessing nitrite content
in culture supernatants. Unlike CpG ODN, which induced high
concentrations of NO, stimulation of BMDCs with polyanhy-
dride NPs did not induce significant amounts of NO
(Figure 4A). Lower concentrations ofmitochondrial superoxide
(mROS) were also observed following NP stimulation com-
pared to CpG ODN treatment (Supplemental Figure 5).
After encountering TLR ligands, murine BMDCs exhibit
a profound metabolic shift away from mitochondrial oxidative
phosphorylation and towards sustained aerobic glycolysis.40
This extended commitment to aerobic glycolysis is
a consequence of the concentration of the innate effector mole-
cule NO. In this context, it must be noted that NO plays an
important antimicrobial role during acute infections and in
response to TLR-stimulation.11,12,41 Because polyanhydride
nanoparticles were observed to activate BMDCs without indu-
cing NO, it was hypothesized that NP stimulation would result
in a BMDC activation phenotype that maintained functional
mitochondria. After an 18-hour stimulation with NP or CpG,
a mitochondrial stress test (MST) was performed on BMDCs
and revealedmarked differences inmetabolic states. CpGODN
stimulation resulted in the expected inhibition of ATP produc-
tion, loss of spare respiratory capacity, and increased proton
leak (Figure 4B and C). In contrast, NP stimulation of BMDCs
resulted in an overall maintenance of mitochondrial function-
ality resembling that of non-stimulated BMDCs (Figures 4B
and C). During the MST, the extracellular acidification rate
(ECAR) was also measured as an indicator of glycolysis. As
expected, the CpG ODN stimulated BMDCs exhibited an
elevated glycolytic rate while NP stimulated cells did not
(Supplemental Figure 6). Together, these results demonstrate
that polyanhydride nanoparticles, while inducing effective DC
activation, induced a distinctly less overt activation phenotype
that avoid excessive production of innate effector molecules
(eg, NO).
Figure 3 Polyanhydride nanoparticles upregulate costimulatory molecule expression on BMDCs and splenic DC populations. Dendritic cells isolated or generated from
naïve BALB/c mice were stimulated for 48 hours with 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating Ova (5% w/w) (NP); CpG ODN plus Ova (CpG); or
unstimulated control as described in materials and methods section. (A) BMDCs gated on MHCII+ and CD11c+, (B) the total MHCII+ and CD11c+ population of DCs
isolated from the spleens, and (C) the CD8α+ subpopulation of splenic DCs was analyzed for costimulatory expression via flow cytometry. Significance was determined via
one-way ANOVA with a Tukey multiple comparison test. P value is indicated as follows *p ≤ 0.05. All graphs represent the treatment average ± SEM.
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Low Antigen Dose Polyanhydride
Nanovaccine Reduced Tumor Burden and
Increased Time on Study
Although high doses of antigen and polyanhydride nanoparti-
cles were effective at inducing CD8+ T cell memory upon
vaccination, experiments were designed to determine whether
lower doses of both Ova and polymer particles could also
induce an efficacious immune response. A lower dose of
Ova (100 µg) and nanoparticles (500 µg) were administered
to mice and the induction of antigen-specific CD8+ T memory
was evaluated. C57BL/6 mice were vaccinated prophylacti-
cally with formulations consisting of the polyanhydride nano-
particles (NP-Ova), sOva alone, or a PBS control. Six weeks
later, mice were challenged subcutaneously with Ova-
expressing E.G7 tumor cells and the progression of tumor
volume monitored (Figure 5A). The number of mice remain-
ing on the study was evaluated at 30 days post-challenge and
only mice immunized with the NP formulation experienced
a significant increase in survival compared to the non-
vaccinated controls and mice receiving sOva alone
(Figure 5B). Together, these results demonstrate that a lower
dose NP vaccine regimen had comparable effectiveness as the
high dose regimen with respect to the induction of an effica-
cious immune response.
Polyanhydride NPs Provided a More
Efficacious Induction of CD8+ T Cell
Memory Upon Vaccination Compared to
CpG ODN
As previous work described overt CpG-induced inflamma-
tory activation of APCs that diverted CD8+ T cell fate
towards effector versus memory phenotypes, the observed
low magnitude pro-inflammatory responses induced by
polyanhydride NPs on DCs may lead to improved recall
responses to challenge.4,7 This led to the hypothesis that the
magnitude and/or consequences of inflammation induced by
different adjuvants would alter the efficacy of the ensuing
immune response. This hypothesis was tested by subcuta-
neously immunizing C57BL/6 mice with vaccine formula-
tions containing a low dose of Ova (100 µg) as described
above: NP, CpGODN, NP + CpGODN, or a naïve PBS only
control. After implantation of the EG.7 cells, tumor volumes
were tracked (Figure 6A) and time on study was compared
(Figure 6B). Anti-Ova antibody titers were also evaluated to
ensure that mice were effectively vaccinated (Supplemental
Figure 7). At 30 days post-tumor challenge, time on study
was significantly improved for mice immunized with either
the NP + Ova formulation or the combination NP + CpG
ODN + Ova formulation compared to unvaccinated control
(Figure 6B). Vaccination with CpG ODN + Ova lead to no
improvement in survival time compared to unvaccinated
controls. These results suggest that polyanhydride nanovac-
cines containing encapsulated antigen are able to initiate
effective T cell memory on their own as well as when co-
administered with the pro-inflammatory TLR agonist
CpG ODN.
Discussion
In this work, the ability of a polyanhydride nanovaccine to
induce CD8+ T cell memory was investigated.
Polyanhydride nanoparticles, encapsulating Ova, enhanced
the development of antigen-specific CD8+ T cell memory
upon vaccination. The induction of this antigen-specific
response occurred without inducing the overt inflamma-
tory responses commonly associated with the use of
microbial-associated molecular patterns (MAMPs) that sti-
mulate immune cells via pattern recognition receptors such
Figure 4 Polyanhydride nanoparticles induce a differential metabolic profile of activation and no induction nitric oxide. BMDCs were stimulated with either NPs, CpG ODN, or
control as described in materials and methods. (A) Nitric oxide production was measure indirectly via Griess assay as nitrite concentration in the cell supernatant 48 hours after
stimulation. BMDCs generated from BALB/c mice were stimulated for 18 hours with, CpG ODN, or non-stimulated control. Stimulated BMDCs were seeded into 24-well seahorse
plates coated with Cell-Tak at a density of 2.5 x 105 cells per well and a mitochondrial stress test (MST) was conducted. (B) Kinetic results of theMSToxygen consumption rate (OCR)
are shown along with (C) ATP production, proton leak, maximal respiratory capacity, and spare respiratory capacity calculated from the MST. Significance between treatments was
determined via one-way ANOVA with a Tukey posttest. P value is indicated as *p ≤ 0.05. All bar graphs and symbols represent the treatment average ± SEM.
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as TLRs.8 Direct in vivo comparison between the TLR
agonist CpG ODN and the polyanhydride nanoparticle
formulation illustrates the relative benefits of a low inflam-
matory vaccine adjuvant formulation on the resulting
CD8+ T cell immune response.
Previously, inclusion of a TLR agonist in the nanoparticle
vaccine formulation negatively affected the ability 20:80
CPTEG:CPH polyanhydride NPs to induce an immune
response that inhibited tumor progression.19,20 Inflammatory
adjuvants, while effective at enhancing antibody production
and expansion of terminally differentiated effector CD8+
Tcells, often fail to induce optimal Tcell memory populations
among other less than optimal outcomes.1,6,39,42,43 Vaccination
strategies that rapidly induce high numbers of CD8+ T cell
memory, such as DC vaccination or antigen-coated particle
formulations, share an important quality.4,42,44,45 The common
feature of these strategies is that they induce CD8+ T cell
memory more effectively when the antigen is delivered in the
absence of overt inflammation (eg, DC-based vaccines).45,46
One component of the overt inflammatory responses
induced by pathogens or TLR-based adjuvants is the pro-
duction of microbicidal innate immune effector molecules
such as NO.47,48 Although NO is important for the innate
immune response to overcome acute pathogenic
infections,49 it has negative autocrine or paracrine effects
on APCs. When NO is produced by BMDCs, it inhibits the
electron transport chain (ie, oxidative phosphorylation)
leading to a dependence on aerobic glycolysis for ATP
production and cellular survival.12,40 This sustained depen-
dence on aerobic glycolysis, while not necessary for acti-
vation, has been described to provide the necessary energy
demands for BMDC survival when stimulated via a TLR
agonist.50 Previous studies have also indicated that mito-
chondrial functional deficiencies are associated with sub-
optimal antigen processing and presentation by APCs.51 In
the present studies, the ability of the NP formulations to
avoid adverse impacts on mitochondrial function in APCs
and a reliance on sustained glycolysis (Figure 4) likely
contributed to a DC phenotype that more effectively pro-
moted the induction of antigen-specific, memory CD8+
T cells (Figures 1 and 5). Furthermore, production of
high amounts of NO by DCs can lead to decreased co-
stimulatory capacity and survival.12,52 Nitric oxide produc-
tion by DCs and other innate immune cells has also been
implicated in the direct inhibition of B cell (ie, antibody
production) and T cell function (ie, effector and memory
phenotypes).36,38,53,54 Pharmacological inhibition of NO
production can prevent some of these deleterious effects
on the adaptive immune response.36,52,55 Compared to the
robust stimulation of DCs by TLR ligands, the low inflam-
matory activation phenotype of DCs following polyanhy-
dride particle stimulation likely contributed to the
enhanced anti-tumor immune response demonstrated in
these studies (Figures 3 and 4).
Figure 5 Polyanhydride nanoparticles induce CD8+ T cell memory with a low antigen dose. C57BL/6 female mice were immunized subcutaneously with formulations
consisting of 75 μg soluble Ova plus 500 μg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 25 μg Ova (NP) (n=12); 100 μg soluble Ova alone (sOva)
(n=11); or PBS control (n=12). Mice were challenged subcutaneously in the flank with E.G7 Ova-expressing tumor cells 42 days post-immunization and (A) tumor volume of
individual mice was tracked. (B) Survival was evaluated 30 days post-challenge. Significance from PBS control was determined using a Log rank (Mantel-Cox) test with
a Bonferroni correction for multiple (2) comparisons. Significance from naïve control group is indicated in the treatment group legend as follows *p ≤ 0.025. Median survival
of each group is also indicated parenthetically.
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Previous intervention strategies targeting the inflamma-
tory response to enhance CD8+ T cell memory have
focused on interfering with chemokine actions and chemo-
kine effects on lymphocytes.56–59 Other strategies have
inhibited the expansion of effector cells at strategic time-
points after immunization, such as dosing with the mTOR
inhibitor rapamycin to interfere with the metabolic
requirements of expanding effector cells in order to shift
differentiation toward memory development.52,60,61
Although these approaches have positively affected DC
activation and memory CD8+ T cell induction, the sys-
temic effects of using these inhibitors may have
unintended consequences. Reducing the magnitude of the
inflammatory response associated with vaccine adjuvants
may be able to provide many of these same benefits with-
out the necessary post-vaccination intervention with inhi-
bitors such as rapamycin. Together, these studies along
with the current observations suggest that induction of
effective adaptive immune memory following vaccination
can be induced using adjuvant formulations that provide
optimal innate activation of APCs with a “just-right”
amount of inflammation.62
Polyanhydride nanoparticle adjuvants have been shown
to be endocytosed by APCs, provide innate immune
Figure 6 Polyanhydride nanoparticles induce effective CD8+ T cell memory as compared to CpG ODN. C57BL/6 female mice (n=12) were immunized subcutaneously with
formulations consisting of 75 μg soluble Ova plus 500 μg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 25 μg Ova (NP); 100 μg soluble Ova adjuvanted
with 20 μg CpG ODN (CpG); a combination of 75 μg soluble Ova plus 500 μg of 20:80 CPTEG:CPH polyanhydride nanoparticles encapsulating 25 μg Ova plus 20 μg CpG
ODN (NP+CpG); or PBS control. Mice were challenged subcutaneously in the flank with E.G7 Ova-expressing tumor cells 42 days post-immunization and (A) tumor volume
of individual mice was tracked. (B) Survival was evaluated 30 days post-challenge. Significance from PBS control was determined using a Log rank (Mantel-Cox) test with
a Bonferroni correction for multiple (3) comparisons. Significance from naïve control group is indicated in the treatment group legend as follows *p ≤ 0.016. Median survival
of each group is also reported parenthetically.
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activation, and induce co-stimulatory molecule upregulation.
These stimulatory capabilities of polyanhydride nanoparti-
cles have contributed to the successful generation of long-
lived protective antibody responses to various encapsulated
protein antigens.15,17,63–65 In the present work, it was shown
that a 20:80 CPTEG:CPH polyanhydride nanoparticle for-
mulation induced antigen-specific CD8+ T cell memory cap-
able of providing protection against a tumor challenge distant
from the vaccination site at both high (Figure 1) and low
dosages of antigen (Figure 5). This immune-enhancing effect
was associated with the ability to activate DCs, particularly
the CD8α+ subpopulation of DCs associated with cross-
priming CD8+ Tcells (Figure 3). Such activation was accom-
plished in the absence of deleterious vaccination site inflam-
mation, which can lead to dysfunctional CD8+ T cell
trafficking and effector functions. Further, it was demon-
strated that the delivery of empty nanoparticles with soluble
antigen did not provide the same benefits as particulate for-
mulations including encapsulated antigen. This finding sug-
gests that there is a critical role for antigen encapsulation in
the capability of polyanhydride NP formulations to induce
CD8+ T cell memory (Figure 2). The benefits of antigen
encapsulation with a single-dose regimen that provide com-
parable results of prime-boost formulations were also
described (Figure 2). Direct in vivo comparison of polyanhy-
dride nanoparticles with the TLR agonist CpG ODN, illus-
trates the effectiveness of the low inflammatory nature at
work to provide significantly greater survival and decreased
tumor burden while the CD8+ T cell memory induced by
CpG ODN vaccination failed to do so (Figure 6). Related to
its phlogistic potential, the addition of CpG ODN to vaccine
formulations has been shown to limit the effectiveness of the
polyanhydride nanovaccine administered by the parenteral
route.4,7,20 This suggests that the nature of the innate inflam-
matory phenotype induced by a vaccine plays a key role in
the outcome of CD8+ Tcell response. It is also of note that, in
this study, the addition of CpG ODN to the polyanhydride
nanoparticle formulation did not have any inhibitory impact.
This observation suggests that the encapsulation of antigen
and persistence of the polyanhydride particles allows the host
to overcome the apparent negative impact of the acute
inflammatory response induced by CpG ODN at the time of
immunization (Figure 6).
In conclusion, these results indicate that the beneficial
effects of polyanhydride nanoparticles arise, in part, from
their ability to activate DCs and upregulate costimulatory
molecule expression without overt induction of inflammatory
cytokines, chemokines, and effector molecules (eg, NO) that
are often associated with a pathogenic infection or TLR ligand
administration. The use of adjuvants that closely mimic the
immunological activation similar to that of a natural infection
has been successful in generating protective antibodymediated
immunity, but many of these adjuvants induce relatively poor
CD8+ T cell responses. By virtue of their low inflammatory
activation properties (ie, selectively pathogen mimicking), the
use of polyanhydride nanovaccines is emerging as a strategy to
more effectively generate CD8+ T cell memory through the
absence of adverse innate inflammatory effects.
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